Placebo | Apremilast 20 mg BID | Apremilast 40 mg QD | |
---|---|---|---|
SF-36 BP with pain VAS | −0.47 | −0.57 | −0.54 |
p | < 0.001 | < 0.001 | < 0.001 |
SF-36 PF with HAQ-DI | −0.14 | −0.46 | −0.73 |
p | NS | < 0.001 | < 0.001 |
SF-36 VT with FACIT-F | 0.41 | 0.66 | 0.55 |
p | < 0.001 | < 0.001 | NS |
↵* Correlations > 0.30 ≤ 0.60 are considered moderate; > 0.60 high. BP: Bodily Pain; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI: Health Assessment Questionnaire Disability Index; NS: not significant; PF: Physical Function; SF-36: 36-Item Medical Outcomes Study Short-Form Health Survey; VAS: visual analog scale; VT: Vitality.